A Dosing Study of Bevacizumab for Retinopathy of Prematurity Late Recurrences and Additional Treatments

Overview of attention for article published in Ophthalmology, June 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news: 1 news outlet
twitter: 8 X users

facebook: 1 Facebook page
f1000: 1 research highlight platform

Readers on

mendeley: 103 Mendeley

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 36,557 followers.

Research from: @MoranEyeCenter @IndianaUniv @TTUHSC @BostonChildrens @EmoryEyeCenter @uiowaeye #ROP @ME_HartnettMD https://t.co/UOO4xs0avi

Research from: @IndianaUniv @MoranEyeCenter @TTUHSC @BostonChildrens @EmoryEyeCenter @uiowaeye https://t.co/2Yl4bbtsbx

RT @AAOjournal: In Retinopathy of Prematurity study using low-dose intravitreal bevacizumab, 11/61 study eyes rec'd add't tx for recurrent…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 4 additional X posts.